



Statement regarding the status of study AC-055B202

Study AC-055B202 was registered into EudraCT (EudraCT number 2010-024211-13).

The aim of this open-label study was to assess the long term safety and tolerability of macitentan in idiopathic pulmonary fibrosis in subjects who had completed the double-blind AC-055B201 study.

Because the primary efficacy endpoint was not met in AC-055B201, it was decided not to conduct the open-label study AC-055B202. So, AC-055B202 has never started, no patients were enrolled and consequently no results can be reported.